Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Journal: Nature medicine
Published: May 10, 2023
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Journal: Investigational new drugs
Published: August 22, 2017
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
Journal: Cancer chemotherapy and pharmacology
Published: April 13, 2016
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Journal: Cancer discovery
Published: January 20, 2016
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 20, 2015
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 06, 2015
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Journal: Molecular cancer therapeutics
Published: August 15, 2014
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 23, 2014
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Journal: Investigational new drugs
Published: March 05, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026